Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
NICE does not recommend ramucirumab (also known as Cyramza and manufactured by Eli Lilly and Company) for people whose stomach cancer has spread or if they have cancer that develops at the point where the food pipe joins to the stomach.
The independent appraisal committee concluded that ramucirumab does not provide enough benefit to patients to justify its high cost and did not qualify for end of life considerations, so it was not recommended.
Source: NICE
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.